, Volume 73, Issue 5, pp 487–493 | Cite as

Mipomersen Sodium: First Global Approval

  • Philip HairEmail author
  • Fiona Cameron
  • Kate McKeage
R&D Insight Report


Mipomersen sodium (Kynamro™) (henceforth mipomersen) is a second-generation antisense oligonucleotide inhibitor of apolipoprotein B-100, which is the main structural component of atherogenic lipid particles. Mipomersen is administered via subcutaneous injection and is indicated as adjunctive treatment for homozygous familial hypercholesterolaemia (HoFH). The drug was developed by Isis Pharmaceuticals, which now collaborates with Genzyme Corporation for on-going development and product marketing. Multinational phase III trials of mipomersen as adjunctive therapy were completed in patients with HoFH, severe FH, heterozygous FH (HeFH) with coronary artery disease (CAD), and in those with hypercholesterolaemia at high risk of CAD. Mipomersen 200 mg once weekly has been approved in the USA as an adjunct to lipid-lowering medications and diet in HoFH patients and is undergoing regulatory review in the EU for the same indication. Genzyme is also conducting a multinational phase III, open-label extension study to evaluate long-term treatment in HoFH and HeFH patients, as well as a multinational trial to evaluate a three-times-per-week mipomersen regimen in patients with severe FH. This article summarises the milestones in the development of once-weekly, subcutaneous mipomersen leading to this first approval.


Statin Therapy Ezetimibe Familial Hypercholesterolaemia Atherogenic Lipid Mipomersen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Gelsinger C, Steinhagen-Thiessen E, Kassner U. Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia. Drugs. 2012;72(11):1445–55.PubMedCrossRefGoogle Scholar
  2. 2.
    Ricotta DN, Frishman W. Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia. Cardiol Rev. 2012;20(2):90–5.Google Scholar
  3. 3.
    Visser ME, Witztum JL, Stroes ESG, et al. Antisense oligonucleotides for the treatment of dyslipidaemia. Eur Heart J. 2012;33(12):1451–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Parhofer KG. Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia. Core Evid. 2012;7:29–38.PubMedCrossRefGoogle Scholar
  5. 5.
    Robinson JG, Goldberg AC. Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3 Suppl.):S18–29.PubMedCrossRefGoogle Scholar
  6. 6.
    Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia. BMJ. 2008;. doi: 10.1136/bmj.a2423.PubMedGoogle Scholar
  7. 7.
    Corporation Genzyme. Kynamro™ (mipomersen sodium): US prescribing information. Cambridge: Genzyme Corporation; 2013.Google Scholar
  8. 8.
    Genzyme, Isis Pharmaceuticals Inc. FDA advisory committee recommends Kynamro™ for homozygous familial hypercholesterolemia [media release]. Accessed 18 Oct 2012.
  9. 9.
    US FDA. FDA approves new orphan drug Kynamro to treat inherited cholesterol disorder [media release]. Accessed 29 Jan 2013. http://www.fda.govt.
  10. 10.
    Genzyme, Isis Pharmaceutcials Inc. Genzyme and Isis announce submission of European marketing authorization application for mipomersen (Kynamro™) [media release]. Accessed 28 Jul 2011.
  11. 11.
    European Medicines Agency. Refusal of the marketing authorisation for Kynamro (mipomersen) [media release]. Accessed 13 Dec 2012.Google Scholar
  12. 12.
    Genzyme, Isis Pharmaceutcials Inc. Genzyme and Isis provide update on CHMP opinion on Kynamro™ (mipomersen) [media release]. Accessed 14 Dec 2012.
  13. 13.
    Isis Pharmaceuticals Inc. Isis reports reduction of apoB-100 levels in a murine model resulting in up to 92% reduction of atherosclerosis [media release]. Accessed 18 Apr 2008.
  14. 14.
    Isis Pharmaceuticals Inc. ISIS 301012 reduces atherosclerotic plaques in animal models [media release]. Accessed 27 Apr 2006.
  15. 15.
    Isis Pharmaceuticals I. Isis Pharmaceuticals’ oral formulation of ISIS 301012 reduces cholesterol in humans [media release]. Accessed 7 Feb 2006.
  16. 16.
    Genzyme Corporation, Isis Pharmaceuticals Inc. Genzyme and Isis complete licensing of mipomersen [media release]. Accessed 24 Jun 2008.
  17. 17.
    Genzyme Corporation, Isis Pharmaceuticals Inc. Genzyme and Isis announce Hart-Scott-Rodino approval of collaboration [media release]. Accessed 1 Feb 2008.
  18. 18.
    Genzyme Corporation, Isis Pharmaceuticals Inc. Genzyme and Isis announce strategic alliance including exclusive worldwide license of mipomersen [media release]. Accessed 7 Jan 2008.
  19. 19.
    Isis Pharmaceuticals Inc. Isis acquires Symphony GenIsis [media release]. Accessed 27 Sep 2007.
  20. 20.
    Isis Pharmaceuticals Inc. Isis Pharmaceuticals and Symphony GenIsis enter into $75 million product development collaboration [media release]. Accessed 7 Apr 2006.
  21. 21.
    Isis Pharmaceuticals Inc. ISIS 301012 produces significant and durable reductions in cholesterol in humans [media release]. Accessed 9 Jun 2005.
  22. 22.
    Bradley J, Crooke R, Graham M. Small, dense, LDL particle concentration is significantly reduced after treatment with an antisense inhibitor of ApoB in healthy volunteers [abstract no. 727]. Circulation. 2005;112(Suppl.):133–4.Google Scholar
  23. 23.
    Merki E, Graham MJ, Mullick AE, et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation. 2008;118(7):743–53.PubMedCrossRefGoogle Scholar
  24. 24.
    Yu RZ, Geary RS, Flaim JD, et al. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2’-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet. 2009;48(1):39–50.PubMedCrossRefGoogle Scholar
  25. 25.
    McGowan MP, Tardif J-C, Ceska R, et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS ONE. 2012;. doi: 10.1371/journal.pone.0049006.Google Scholar
  26. 26.
    Cromwell WC, Thomas GS, Boltje I, et al. Safety and efficacy of mipomersen administered as addon therapy in patients with hypercholesterolemia and high cardiovascular risk+. Annual Scientific Sessions of the National Lipid Association, 31 May–3 Jun 2012; Scottsdale.Google Scholar
  27. 27.
    Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulations. 2012;126(19):2283–92.CrossRefGoogle Scholar
  28. 28.
    Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9719):998–1006.PubMedCrossRefGoogle Scholar
  29. 29.
    Parhofer KG, Vogt A. Mipomersen, an APOB synthesis inhibitor, evaluation of potential to reduce necessity for lipid-apheresis in patients with heterozygous FH and CAD [abstract]. 79th European Athersclerosis Society Congress, 26–29 Jun 2011. Gothenburg; 2011.Google Scholar
  30. 30.
    Duell PB, Santos RD, East C, et al. Long-term safety and efficacy of mipomersen in patients with familial hypercholesterolemia uncontrolled by maximally tolerated lipid lowering therapy. Annual Scientific Sessions of the National Lipid Association, 31 May–3 Jun 2012. Scottsdale.Google Scholar
  31. 31.
    Akdim F, Stroes ESG, Sijbrands EJG, et al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol. 2010;55(15):1611–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Akdim F, Visser ME, Tribble DL, et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol. 2010;105(10):1413–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Akdim F, Tribble DL, Flaim JD, et al. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J. 2011;32(21):2650–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Kastelein JJP, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation. 2006;114(16):1729–35.PubMedCrossRefGoogle Scholar
  35. 35.
    Visser ME, Wagener G, Baker BF, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2012;33(9):1142–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Visser ME, Akdim F, Tribble DL, et al. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res. 2010;51(5):1057–62.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.Adis R & D InsightAucklandNew Zealand
  2. 2.AdisAucklandNew Zealand

Personalised recommendations